| Literature DB >> 32637317 |
Dongbo Cai1, Jiang Zhu1, Yang Li1, Lingfeng Li1, Meng Zhang1, Zhi Wang2, Hanbo Yang3, Junhui Li4, Zhifan Yang1, Shouwen Chen1.
Abstract
Bacitracin is a broad-spectrum cyclic peptide antibiotic mainly produced by Bacillus, precursor amino acid supply served as the critical role during its synthesis. In this study, we systematically engineered branch-chain amino acid (BCAA) supply modules for bacitracin production. Firstly, we demonstrated that Ile and Leu acted as limiting precursors for bacitracin synthesis, and that BCAA synthetic pathways were strengthened via simultaneous overexpression of, feedback-resistance acetolactate synthase IlvBNfbr, 2-isopropylmalate synthetase LeuAfbr and BCAA aminotransferase YbgE. Using this approach, bacitracin yield from strain DW-BCAA2 was 892.54 U/mL, an increase of 18.32% compared with that DW2 (754.32 U/mL). Secondly, the BCAA permeases, YvbW and BraB, which have higher affinities for Leu and Ile transportation, respectively, were both identified as BCAA importers, with their overexpression improving intracellular BCAA accumulations and bacitracin yields. Finally, the leucine-responsive family regulator, lrpC was deleted to generate the final strain DW-BCAA6, with intracellular concentrations of Ile, Leu and Val increased by 2.26-, 1.90- and 0.72-fold, respectively. The bacitracin yield from DW-BCAA6 was 1029.83 U/mL, an increase of 36.52%, and is the highest bacitracin yield reported. Equally, concentrations of other byproducts including acetic acid, acetoin and 2,3-butanediol were all reduced. Taken together, we devised an efficient strategy for the enhanced production of bacitracin, and a promising B. licheniformis DW-BCAA6 strain was constructed for industrial production of bacitracin.Entities:
Keywords: Bacillus licheniformis; Bacitracin; Branch-chain amino acid permease; Branch-chain amino acids; lrpC
Year: 2020 PMID: 32637317 PMCID: PMC7326738 DOI: 10.1016/j.mec.2020.e00136
Source DB: PubMed Journal: Metab Eng Commun ISSN: 2214-0301
Fig. 2Metabolic engineering of BCAA synthetic, transportation and regulation modules for enhanced production of bacitracin in B. licheniformis DW2.
The strains and plasmids used in this research.
| Strains and plasmids | Relevant properties | Source of reference |
|---|---|---|
| Strains | ||
| This study | ||
| Wide-type CCTCC M2011344 | CCTCC | |
| DW2/pHY-ilvA | DW2 harboring IlvA expression vector pHY-ilvA | This study |
| DW2/pHY-ilvBN | DW2 harboring IlvBN expression vector pHY-ilvBN | This study |
| DW2/pHY-ilvCD | DW2 harboring IlvCD expression vector pHY-ilvCD | This study |
| DW2/pHY-leuA | DW2 harboring LeuA expression vector pHY-leuA | This study |
| DW2/pHY-leuB | DW2 harboring LeuB expression vector pHY-leuB | This study |
| DW2/pHY-leuC | DW2 harboring LeuC expression vector pHY-leuC | This study |
| DW2/pHY-leuD | DW2 harboring LeuD expression vector pHY-leuD | This study |
| DW2/pHY-300 | DW2 harboring pHY300PLK, as control strain | This study |
| DW2/pHY-ilvBNfbr | DW2 harboring IlvBNfbr expression vector pHY-ilvBNfbr | This study |
| DW2/pHY-leuAfbr | DW2 harboring LeuAfbr expression vector pHY-leuAfbr | This study |
| DW2-ilvBNfbr | IlvBNfbr integration overexpression strain | This study |
| DW2-leuAfbr | LeuAfbr integration overexpression strain | This study |
| DW-BCAA1 | IlvBNfbr and LeuAfbr integration overexpression strain | This study |
| DW-BCAA1/pHY300 | DW-BCAA1 harboring pHY300PLK | This study |
| DW-BCAA1/pHY-IlvE | DW-BCAA1 harboring IlvE expression vector pHY-IlvE | This study |
| DW-BCAA1/pHY-YbgE | DW-BCAA1 harboring YbgE expression vector pHY-YbgE | This study |
| DW-BCAA1/pHY-YwaA | DW-BCAA1 harboring YwaA expression vector pHY-YwaA | This study |
| DW-BCAA2 | Overexpression of YbgE via promoter replacement in DW-BCAA1 | This study |
| DW2△yvbW | Deleting | This study |
| DW2/pHY-YvbW | DW2 harboring YvbW expression vector pHY-YvbW | This study |
| DW2△BraB | Deleting | This study |
| DW2/pHY-BraB | DW2 harboring BraB expression vector pHY-BraB | This study |
| DW-BCAA3 | Overexpression of YvbW via promoter replacement in DW-BCAA2 | This study |
| DW-BCAA4 | Overexpression of BraB via promoter replacement in DW-BCAA2 | This study |
| DW-BCAA5 | Simultaneously overexpressing YvbW and BraB via promoter replacement in DW-BCAA2 | This study |
| DW-BCAA6 | Deleting regulator gene | This study |
| Plasmids | ||
| pHY300PLK | Lab collection | |
| T2(2)-Ori | Lab collection | |
| pHY-ilvA | IlvA expression vcctor based on pHY300PLK | This study |
| pHY-ilvBN | IlvBN expression vcctor based on pHY300PLK | This study |
| pHY-ilvCD | IlvCD expression vcctor based on pHY300PLK | This study |
| pHY-leuA | LeuA expression vcctor based on pHY300PLK | This study |
| pHY-leuB | LeuB expression vcctor based on pHY300PLK | This study |
| pHY-leuC | LeuC expression vcctor based on pHY300PLK | This study |
| pHY-leuD | LeuD expression vcctor based on pHY300PLK | This study |
| pHY-ilvBNfbr | IlvBNfbr expression vcctor based on pHY300PLK | This study |
| pHY-leuAfbr | LeuAfbr expression vcctor based on pHY300PLK | This study |
| pHY-IlvE | IlvE expression vcctor based on pHY300PLK | This study |
| pHY-YbgE | YbgE expression vcctor based on pHY300PLK | This study |
| pHY-YwaA | YwaA expression vcctor based on pHY300PLK | This study |
| T2-::ilvBNfbr | T2(2)-Ori- | This study |
| T2-::leuAfbr | T2(2)-Ori- | This study |
| T2-PbacA-PybgE | T2(2)-Ori-PybgE(A + PbacA + B); to replace the promoter of | This study |
| T2-PbacA-PyvbW | T2(2)-Ori-PyvbW(A + PbacA + B); to replace the promoter of | This study |
| T2-PbacA-PbraB | T2(2)-Ori-PbraB(A + PbacA + B); to replace the promoter of | This study |
| T2-lrpC | T2(2)-Ori- | This study |
Fig. 1Effects of Ile, Leu and Val additions on bacitracin production. A: Effects of 40 mg/L Ile, Leu and Val addition at different time points on bacitracin production, respectively. B: Effects of different concentrations of Ile and Leu additions at 18 h on bacitracin production, respectively. Each experiment was repeated at least three times, and data are represented as the means of three replicates and bars represent the standard deviations, ∗, P < 0.05; and ∗∗, P < 0.01 indicate the significance levels between recombinant strains and control strain.
Fig. 3Effects of strengthening BCAA synthetic pathways on bacitracin production. A: Effects of overexpression of ilvA, ilvBN, ilvCD, leuA, leuB, leuC, leuD on bacitracin yields, B: overexpression of the feedback resistant IlvBNfbr and LeuAfbr improved bacitraicn production, C: The concentrations of intracellular BCAAs, D: The concentrations of extracellular BCAAs. Each experiment was repeated at least three times, and data are represented as the means of three replicates and bars represent the standard deviations, ∗, P < 0.05; and ∗∗, P < 0.01 indicate the significance levels between recombinant strains and control strain.
The activities of acetolactate synthetase and 2-isopropylmalate synthetase in IlvBN and LeuA overexpression strains.
| Strains | Acetolactate synthetase (U/mL) | 2-isopropylmalate synthetase (U/mL) |
|---|---|---|
| DW2/pHY300 | 14.32 | 9.53 |
| DW2/pHY-ilvBN | 31.42 | – |
| DW2/pHY-leuA | – | 16.42 |
| DW2/pHY-ilvBNfbr | 48.53 | – |
| DW2/pHY-leuAfbr | – | 23.19 |
Fig. 4Effects of BCAA aminotransferase overexpressions on bacitracin production. A: Effects of ilvE, ywaA and ybgE overexperessions on bacitracin yields, B: Effects of replacing the promoter of ybgE by PbacA on bacitracin production, C: The concentrations of intracellular BCAAs, D: The concentrations of extracellular BCAAs. Each experiment was repeated at least three times, and data are represented as the means of three replicates and bars represent the standard deviations, ∗, P < 0.05; and ∗∗, P < 0.01 indicate the significance levels between recombinant strains and control strain.
Fig. 5Identification of BCAA permeases, YvbW and BraB, in Effects of overexpression and deletion of yvbW and braB on bacitracin production, B: The concentrations of intracellular BCAAs, C: The concentrations of extracellular BCAAs, D: The concentrations of extracellular BCAAs of DW2/pHY300, E: The concentrations of extracellular BCAAs of DW2/pHY-YvbW, F: The concentrations of extracellular BCAAs of DW2/pHY-BraB. Each experiment was repeated at least three times, and data are represented as the means of three replicates and bars represent the standard deviations, ∗, P < 0.05; and ∗∗, P < 0.01 indicate the significance levels between recombinant strains and control strain.
Fig. 6Engineering BCAA permeases, YvbW and BraB, for enhancement production of bacitracin. A: Strengthening YvbW and BraB expressions improved bacitracin production. B: The concentrations of intracellular BCAAs, C: The concentrations of extracellular BCAAs. Each experiment was repeated at least three times, and data are represented as the means of three replicates and bars represent the standard deviations, ∗, P < 0.05; and ∗∗, P < 0.01 indicate the significance levels between recombinant strains and control strain.
Fig. 7Effects of Deletion of lrpC improved bacitracin yield, B: The transcriptional level of BCAA transporter gene brnQ, C: The schematic diagram of GFP expression vector mediated by promoter PbrnQ, D: The green fluorescence intensities of recombinant strains. Each experiment was repeated at least three times, and data are represented as the means of three replicates and bars represent the standard deviations, ∗, P < 0.05; and ∗∗, P < 0.01 indicate the significance levels between recombinant strains and control strain.
Fig. 8Fermentation processes of Bacitracin yields and cell biomasses of DW2 and DW-BCAA6 during bacitracin production, B: The concentrations of intracellular BCAAs, C: The concentrations of extracellular BCAAs, D: The concentrations of main byproducts, acetic acid, acetoin and 2,3-butanediol. Each experiment was repeated at least three times, and data are represented as the means of three replicates and bars represent the standard deviations, ∗, P < 0.05; and ∗∗, P < 0.01 indicate the significance levels between recombinant strains and control strain.